Howard R L, Schrier R W
Department of Medicine, University of Colorado School of Medicine, Denver.
Horm Res. 1990;34(3-4):118-23. doi: 10.1159/000181809.
Sodium and water retention is characteristic of edematous disorders including cardiac failure, cirrhosis, nephrotic syndrome, and pregnancy. In recent years, the use of a sensitive radioimmunoassay for plasma vasopressin has implicated the role of nonosmotic vasopressin release in the water retention of these edematous disorders. In experimental studies and studies in man, it has been found that the nonosmotic release of vasopressin is consistently associated with the activation of the sympathetic nervous and renin-angiotensin-aldosterone systems. Moreover, the sympathetic nervous system has been shown to be involved in the nonosmotic release of vasopressin (carotid and aortic baroreceptors) and in the activation of the renin-angiotensin system (renal beta-adrenergic receptors). These findings have led to our proposal that body fluid volume regulation involves the dynamic interaction between cardiac output and peripheral arterial resistance. In this context, neither total extracellular-fluid (ECF) volume nor blood volume are determinants of renal sodium and water excretion. Rather, renal sodium and water retention is initiated by either a fall in cardiac output (e.g. ECF volume depletion, low-output cardiac failure, pericardial tamponade, or hypovolemic nephrotic syndrome) or peripheral arterial vasodilation (e.g. high-output cardiac failure, cirrhosis, pregnancy, sepsis, arteriovenous fistulae, and pharmacologic vasodilators). With a decrease in effective arterial blood volume (EABV). initiated by either a fall in cardiac output or peripheral arterial vasodilation, the acute response involves vasoconstriction mediated by angiotensin, sympathetic mediators, and vasopressin. The slower response to restoring EABV involves vasopressin-mediated water retention and aldosterone-mediated sodium retention. The renal vasoconstriction which accompanies those states that decrease EABV, by either decreasing cardiac output or causing peripheral arterial vasodilation.(ABSTRACT TRUNCATED AT 250 WORDS)
钠和水潴留是包括心力衰竭、肝硬化、肾病综合征及妊娠在内的水肿性疾病的特征。近年来,一种用于检测血浆血管加压素的灵敏放射免疫测定法的应用表明,非渗透性血管加压素释放参与了这些水肿性疾病的水潴留过程。在实验研究及人体研究中发现,血管加压素的非渗透性释放始终与交感神经系统及肾素 - 血管紧张素 - 醛固酮系统的激活相关。此外,已表明交感神经系统参与血管加压素的非渗透性释放(颈动脉和主动脉压力感受器)及肾素 - 血管紧张素系统的激活(肾β - 肾上腺素能受体)。这些发现促使我们提出,体液容量调节涉及心输出量与外周动脉阻力之间的动态相互作用。在此背景下,细胞外液(ECF)总量及血容量均非肾钠和水排泄的决定因素。相反,肾钠和水潴留要么由心输出量下降(如ECF容量减少、低输出量心力衰竭、心包填塞或低血容量性肾病综合征),要么由外周动脉血管舒张(如高输出量心力衰竭、肝硬化、妊娠、脓毒症、动静脉瘘及药物性血管扩张剂)引发。随着有效动脉血容量(EABV)因心输出量下降或外周动脉血管舒张而减少,急性反应涉及由血管紧张素、交感神经介质及血管加压素介导的血管收缩。恢复EABV的较慢反应涉及血管加压素介导的水潴留及醛固酮介导的钠潴留。伴随那些因心输出量下降或外周动脉血管舒张而使EABV减少的状态出现的肾血管收缩……(摘要截选至250词)